MUC1 drives c-Met-dependent migration and scattering

Teresa M. Horm, Benjamin G. Bitler, Derrick M. Broka, Jeanne M. Louderbough, Joyce Schroeder

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The transmembrane mucin MUC1 is overexpressed in most ductal carcinomas, and its overexpression is frequently associated with metastatic progression. MUC1 can drive tumor initiation and progression via interactions with many oncogenic partners, including β-catenin, the EGF receptor (EGFR) and Src. The decoy peptide protein transduction domain MUC1 inhibitory peptide (PMIP) has been shown to inhibit the tumor promoting activities of MUC1 in breast and lung cancer, including cell growth and invasion, and its usage suppresses metastatic progression in mouse models of breast cancer. To further characterize the reduced metastasis observed upon PMIP treatment, we conducted motility assays and observed that PMIP inhibits cell motility of breast cancer cells. To determine the mechanism by which PMIP inhibits motility, we evaluated changes in global gene transcription upon PMIP treatment, and identi fied a number of genes with altered expression in response to PMIP. Among these genes is the metastatic mediator, c-Met, a transmembrane tyrosine kinase that can promote cell scattering, migration, and invasion. To further investigate the role of c-Met in MUC1-dependent metastatic events, we evaluated the effects of MUC1 expression and EGFR activation on breast cancer cell scattering, branching, and migration. We found that MUC1 strongly promoted all of these events and this effect was further amplified by EGF treatment. Importantly, the effect of MUC1 and EGF on these phenotypes was dependent upon c-Met activity. Overall, these results indicate that PMIP can block the expression of a key metastatic mediator, further advancing its potential use as a clinical therapeutic.

Original languageEnglish (US)
Pages (from-to)1544-1554
Number of pages11
JournalMolecular Cancer Research
Volume10
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Peptides
Breast Neoplasms
Epidermal Growth Factor Receptor
Epidermal Growth Factor
Cell Movement
Genes
Catenins
Ductal Carcinoma
Mucins
Protein Domains
Protein-Tyrosine Kinases
Lung Neoplasms
Neoplasms
Neoplasm Metastasis
Phenotype
Growth
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

MUC1 drives c-Met-dependent migration and scattering. / Horm, Teresa M.; Bitler, Benjamin G.; Broka, Derrick M.; Louderbough, Jeanne M.; Schroeder, Joyce.

In: Molecular Cancer Research, Vol. 10, No. 12, 12.2012, p. 1544-1554.

Research output: Contribution to journalArticle

Horm, TM, Bitler, BG, Broka, DM, Louderbough, JM & Schroeder, J 2012, 'MUC1 drives c-Met-dependent migration and scattering', Molecular Cancer Research, vol. 10, no. 12, pp. 1544-1554. https://doi.org/10.1158/1541-7786.MCR-12-0296
Horm, Teresa M. ; Bitler, Benjamin G. ; Broka, Derrick M. ; Louderbough, Jeanne M. ; Schroeder, Joyce. / MUC1 drives c-Met-dependent migration and scattering. In: Molecular Cancer Research. 2012 ; Vol. 10, No. 12. pp. 1544-1554.
@article{410f68aeb42b4771b3c12e99cc1ff477,
title = "MUC1 drives c-Met-dependent migration and scattering",
abstract = "The transmembrane mucin MUC1 is overexpressed in most ductal carcinomas, and its overexpression is frequently associated with metastatic progression. MUC1 can drive tumor initiation and progression via interactions with many oncogenic partners, including β-catenin, the EGF receptor (EGFR) and Src. The decoy peptide protein transduction domain MUC1 inhibitory peptide (PMIP) has been shown to inhibit the tumor promoting activities of MUC1 in breast and lung cancer, including cell growth and invasion, and its usage suppresses metastatic progression in mouse models of breast cancer. To further characterize the reduced metastasis observed upon PMIP treatment, we conducted motility assays and observed that PMIP inhibits cell motility of breast cancer cells. To determine the mechanism by which PMIP inhibits motility, we evaluated changes in global gene transcription upon PMIP treatment, and identi fied a number of genes with altered expression in response to PMIP. Among these genes is the metastatic mediator, c-Met, a transmembrane tyrosine kinase that can promote cell scattering, migration, and invasion. To further investigate the role of c-Met in MUC1-dependent metastatic events, we evaluated the effects of MUC1 expression and EGFR activation on breast cancer cell scattering, branching, and migration. We found that MUC1 strongly promoted all of these events and this effect was further amplified by EGF treatment. Importantly, the effect of MUC1 and EGF on these phenotypes was dependent upon c-Met activity. Overall, these results indicate that PMIP can block the expression of a key metastatic mediator, further advancing its potential use as a clinical therapeutic.",
author = "Horm, {Teresa M.} and Bitler, {Benjamin G.} and Broka, {Derrick M.} and Louderbough, {Jeanne M.} and Joyce Schroeder",
year = "2012",
month = "12",
doi = "10.1158/1541-7786.MCR-12-0296",
language = "English (US)",
volume = "10",
pages = "1544--1554",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - MUC1 drives c-Met-dependent migration and scattering

AU - Horm, Teresa M.

AU - Bitler, Benjamin G.

AU - Broka, Derrick M.

AU - Louderbough, Jeanne M.

AU - Schroeder, Joyce

PY - 2012/12

Y1 - 2012/12

N2 - The transmembrane mucin MUC1 is overexpressed in most ductal carcinomas, and its overexpression is frequently associated with metastatic progression. MUC1 can drive tumor initiation and progression via interactions with many oncogenic partners, including β-catenin, the EGF receptor (EGFR) and Src. The decoy peptide protein transduction domain MUC1 inhibitory peptide (PMIP) has been shown to inhibit the tumor promoting activities of MUC1 in breast and lung cancer, including cell growth and invasion, and its usage suppresses metastatic progression in mouse models of breast cancer. To further characterize the reduced metastasis observed upon PMIP treatment, we conducted motility assays and observed that PMIP inhibits cell motility of breast cancer cells. To determine the mechanism by which PMIP inhibits motility, we evaluated changes in global gene transcription upon PMIP treatment, and identi fied a number of genes with altered expression in response to PMIP. Among these genes is the metastatic mediator, c-Met, a transmembrane tyrosine kinase that can promote cell scattering, migration, and invasion. To further investigate the role of c-Met in MUC1-dependent metastatic events, we evaluated the effects of MUC1 expression and EGFR activation on breast cancer cell scattering, branching, and migration. We found that MUC1 strongly promoted all of these events and this effect was further amplified by EGF treatment. Importantly, the effect of MUC1 and EGF on these phenotypes was dependent upon c-Met activity. Overall, these results indicate that PMIP can block the expression of a key metastatic mediator, further advancing its potential use as a clinical therapeutic.

AB - The transmembrane mucin MUC1 is overexpressed in most ductal carcinomas, and its overexpression is frequently associated with metastatic progression. MUC1 can drive tumor initiation and progression via interactions with many oncogenic partners, including β-catenin, the EGF receptor (EGFR) and Src. The decoy peptide protein transduction domain MUC1 inhibitory peptide (PMIP) has been shown to inhibit the tumor promoting activities of MUC1 in breast and lung cancer, including cell growth and invasion, and its usage suppresses metastatic progression in mouse models of breast cancer. To further characterize the reduced metastasis observed upon PMIP treatment, we conducted motility assays and observed that PMIP inhibits cell motility of breast cancer cells. To determine the mechanism by which PMIP inhibits motility, we evaluated changes in global gene transcription upon PMIP treatment, and identi fied a number of genes with altered expression in response to PMIP. Among these genes is the metastatic mediator, c-Met, a transmembrane tyrosine kinase that can promote cell scattering, migration, and invasion. To further investigate the role of c-Met in MUC1-dependent metastatic events, we evaluated the effects of MUC1 expression and EGFR activation on breast cancer cell scattering, branching, and migration. We found that MUC1 strongly promoted all of these events and this effect was further amplified by EGF treatment. Importantly, the effect of MUC1 and EGF on these phenotypes was dependent upon c-Met activity. Overall, these results indicate that PMIP can block the expression of a key metastatic mediator, further advancing its potential use as a clinical therapeutic.

UR - http://www.scopus.com/inward/record.url?scp=84871361268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871361268&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-12-0296

DO - 10.1158/1541-7786.MCR-12-0296

M3 - Article

C2 - 23193156

AN - SCOPUS:84871361268

VL - 10

SP - 1544

EP - 1554

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 12

ER -